China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced that its clinical trial filing for HY3000 nasal spray, a Category 1 chemical drug targeting COVID-19, has been accepted for review by the National Medical Products Administration (NMPA).
Drug Details
HY3000 is a novel polypeptide membrane fusion inhibitor that binds to the HR1 region of the novel coronavirus spike protein. It prevents the formation of the virus’s six-helix bundle structure, thereby blocking the virus from infecting cells and achieving an antiviral effect. HY3000 has a unique mechanism of action and a conserved target site, making it unaffected by coronavirus mutations. It demonstrates high activity against major epidemic strains, including Omicron. Administered via nasal spray, HY3000 acts directly on the respiratory tract, the primary site of viral invasion, to suppress the virus early.-Fineline Info & Tech
